Please assess the completion status of the following clinical trial:

Trial Title: The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women must meet all of the following inclusion criteria:~1. Age 15-40 at the time of enrollment (Note: Participants between the ages of 15-17 will require written informed consent from parent/legal guardian. Written assent will also be obtained from the minor)~2. Acute PID, defined by symptoms and signs guided by current CDC guidelines:50~   1. Current symptoms of lower abdominal or pelvic pain (present for ≤30 days) AND~  2. Cervical motion tenderness AND/OR uterine tenderness AND/OR adnexal tenderness on pelvic examination~3. Ability to provide written informed consent~Exclusion Criteria:~Women with any of the following will be ineligible to participate:~1. Pregnant or nursing a baby (Note: a urine pregnancy test will be done at enrollment. Result must be negative to participate in the study.)~2. Uterine procedure (e.g. dilation and curettage, abortion) or miscarriage within the past 6 weeks.~3. Allergy to any of the study medications (cephalosporins, doxycycline, or metronidazole) or Type 1 hypersensitivity allergic reaction to penicillin for those with unknown tolerance to cephalosporins.~4. Systemic or vaginal antibiotic therapy in the preceding 7 days~5. Requires inpatient PID therapy (per the current CDC guidelines)50~6. Inability to obtain an endometrial biopsy at enrollment~7. Known inability to comply with the follow-up visits~8. Prior hysterectomy~9. Menopause (including natural menopause defined as lack of menses for 12 consecutive months \[in the absence of pregnancy\] and surgical menopause defined as a woman who has had both ovaries removed)~10. Inability to swallow pills~11. Not willing to refrain from alcohol during the two week treatment period (and two additional days following completion of study medication)~12. Other condition present at enrollment that requires additional antibiotic treatment~13. Current use of any of the following medications:~    * Anticoagulants, coumarin- or indandione-derivative: warfarin~   * cimetidine (Tagamet)~   * Disulfiram~   * Seizure medications including: phenytoin (Dilantin), carbamezapine (Tegretol), barbiturates (i.e. Phenobarbital)~   * Lithium~   * Immunosuppressive drugs including: cyclosporine, amprenavir~   * Antacids, minerals or bismuth subsalicylate (Pepto Bismol)~14. Any condition, in the opinion of the investigator that would interfere with the participant's safety or with study outcomes~15. Participation in any study involving an investigational product in the past 30 days or anticipation of participation in any study using an investigational product in the next 30 days~16. Previous participation in this study~17. Evidence of a tuboovarian abscess

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ceftriaxone/Doxycycline/Placebo Oral Cap (Type: PLACEBO_COMPARATOR): ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
- Ceftriaxone, Doxycycline, Metronidazole (Type: ACTIVE_COMPARATOR): ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).